These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3145895)

  • 1. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
    Matsunaga H; Kuwahara Y; Kusugami K; Morise K; Shimokata K
    Gastroenterol Jpn; 1988 Oct; 23(5):527-33. PubMed ID: 3145895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.
    Karimine N; Arinaga S; Inoue H; Nanbara S; Ueo H; Akiyoshi T
    Clin Exp Immunol; 1994 Jun; 96(3):484-90. PubMed ID: 8004819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of lymphokine-activated killer cell activity in patients with gastrointestinal cancer.
    Sedman PC; Ramsden CW; Brennan TG; Giles GR; Guillou PJ
    Br J Surg; 1988 Jun; 75(6):591-4. PubMed ID: 3134974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation and biological activity of interleukin 12.
    Lee SM; Suen Y; Qian J; Knoppel E; Cairo MS
    Leuk Lymphoma; 1998 May; 29(5-6):427-38. PubMed ID: 9643557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients.
    Staren ED; Economou SG; Harris JE; Braun DP
    Cancer; 1989 Dec; 64(11):2238-42. PubMed ID: 2804913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
    Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
    Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 and interferon-gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer.
    Kusugami K; Matsuura T; Kawase T; Ina K; Matsunaga H; Kuwahara Y; Inagaki T; Morise K; Shimokata K
    Gastroenterol Jpn; 1990 Jun; 25(3):306-13. PubMed ID: 1972685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
    Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
    Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
    Nakamura H; Ishiguro K; Mori T
    Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity.
    Hsu DH; Moore KW; Spits H
    Int Immunol; 1992 May; 4(5):563-9. PubMed ID: 1627494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
    Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
    Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine production and cytotoxicity of lymphocytes in patients on maintenance short- or long-term haemodialysis.
    Hayakawa M; Hatano T; Sunabe T; Higa I; Osawa A
    Nephrol Dial Transplant; 1994; 9(6):655-61. PubMed ID: 7970092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of human NK cells and generation of LAK activity.
    Whiteside TL
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
    Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
    Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
    Hermann GG; Petersen KR; Steven K; Zeuthen J
    J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
    Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
    Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro].
    Yoshimura A
    Nihon Ika Daigaku Zasshi; 1990 Jun; 57(3):211-21. PubMed ID: 2376610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.